Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | AXA Investment Managers S.A. |
| Company dealt in | Applegreen PLC |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | € 0.01 ordinary shares |
| Date of dealing | 14th January 2021 |
| Long | Short | |||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | 2,643,750 (2.19%) | |||||
| (2) Derivatives (other than options) | ||||||
| (3) Options and agreements to purchase/sell | ||||||
| Total | 2,643,750 (2.19%) | |||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | ||||||
|
(2) Derivatives (other than options) |
||||||
|
(3) Options and agreements to purchase/sell |
||||||
| Total | ||||||
Ap20
|
Purchase/sale |
Number of relevant securities |
Price per unit (Note 5) |
| Sale | 200,000 | GBP 5.04 |
(b) Derivatives transactions (other than options transactions)
| Product name,
e.g. CFD |
Nature of transaction
(Note 6) |
Number of relevant securities
(Note 7) |
Price per unit
(Note 5) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option |
Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
(ii) Exercising
| Product name,
e.g. call option |
Number of securities | Exercise price per unit (Note 5) |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction
(Note 8) |
Details | Price per unit
(if applicable) (Note 5) |
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
| Date of disclosure | 15th January 2021 |
| Contact name | Victoria Warmé |
| Telephone number | +33 (0) 1 44 45 83 60 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection (Note 10) |
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | AXA Investment Managers S.A. |
| Company dealt in | Applegreen PLC |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | € 0.01 ordinary shares |
| Date of dealing | 14th January 2021 |
| Long | Short | |||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | 2,643,750 (2.19%) | |||||
| (2) Derivatives (other than options) | ||||||
| (3) Options and agreements to purchase/sell | ||||||
| Total | 2,643,750 (2.19%) | |||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | ||||||
|
(2) Derivatives (other than options) |
||||||
|
(3) Options and agreements to purchase/sell |
||||||
| Total | ||||||
Ap20
|
Purchase/sale |
Number of relevant securities |
Price per unit (Note 5) |
| Sale | 2,000,000 | GBP 5.04 |
(b) Derivatives transactions (other than options transactions)
| Product name,
e.g. CFD |
Nature of transaction
(Note 6) |
Number of relevant securities
(Note 7) |
Price per unit
(Note 5) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option |
Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
(ii) Exercising
| Product name,
e.g. call option |
Number of securities | Exercise price per unit (Note 5) |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction
(Note 8) |
Details | Price per unit
(if applicable) (Note 5) |
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
| Date of disclosure | 18th January 2021 |
| Contact name | Victoria Warmé |
| Telephone number | +33 (0) 1 44 45 83 60 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection (Note 10) |
New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…